Literature DB >> 9741573

Primary pulmonary hypertension between inflammation and cancer.

N F Voelkel1, C Cool, S D Lee, L Wright, M W Geraci, R M Tuder.   

Abstract

We believe that the monoclonal cell expansion in primary pulmonary hypertension is the result of autonomous growth of stem cell-like endothelial cells, whereas the polyclonal proliferation in secondary pulmonary hypertension occurs as a response of endothelial cells to exogenous stimuli (like viral infection or high shear stress). In this context, we propose that different transcriptional and translational events govern the growth and expansion of monoclonal when compared with polyclonal pulmonary endothelial cells. The availability of antibodies directed against specific tyrosine kinase proteins involved in vasculogenesis/angiogenesis now permits the identification and localization of the components of such a misguided angiogenesis cell proliferation program in the pulmonary hypertensive vascular lesions.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9741573     DOI: 10.1378/chest.114.3_supplement.225s

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  62 in total

Review 1.  Pulmonary arterial hypertension: new ideas and perspectives.

Authors:  N Galiè; A Torbicki
Journal:  Heart       Date:  2001-04       Impact factor: 5.994

2.  Idiopathic pulmonary arterial hypertension: an avian model for plexogenic arteriopathy and serotonergic vasoconstriction.

Authors:  Robert F Wideman; Krishna R Hamal
Journal:  J Pharmacol Toxicol Methods       Date:  2011-01-26       Impact factor: 1.950

3.  Targeting energetic metabolism: a new frontier in the pathogenesis and treatment of pulmonary hypertension.

Authors:  Rubin M Tuder; Laura A Davis; Brian B Graham
Journal:  Am J Respir Crit Care Med       Date:  2011-11-10       Impact factor: 21.405

Review 4.  Basic science of pulmonary arterial hypertension for clinicians: new concepts and experimental therapies.

Authors:  Stephen L Archer; E Kenneth Weir; Martin R Wilkins
Journal:  Circulation       Date:  2010-05-11       Impact factor: 29.690

5.  Epigenetic attenuation of mitochondrial superoxide dismutase 2 in pulmonary arterial hypertension: a basis for excessive cell proliferation and a new therapeutic target.

Authors:  Stephen L Archer; Glenn Marsboom; Gene H Kim; Hannah J Zhang; Peter T Toth; Eric C Svensson; Jason R B Dyck; Mardi Gomberg-Maitland; Bernard Thébaud; Aliya N Husain; Nicole Cipriani; Jalees Rehman
Journal:  Circulation       Date:  2010-06-07       Impact factor: 29.690

Review 6.  One hundred years of research in the pathogenesis of pulmonary hypertension.

Authors:  Ari Zaiman; Iwona Fijalkowska; Paul M Hassoun; Rubin M Tuder
Journal:  Am J Respir Cell Mol Biol       Date:  2005-11       Impact factor: 6.914

Review 7.  Pathology of pulmonary hypertension.

Authors:  Rubin M Tuder; John C Marecki; Amy Richter; Iwona Fijalkowska; Sonia Flores
Journal:  Clin Chest Med       Date:  2007-03       Impact factor: 2.878

8.  The cancer paradigm of severe pulmonary arterial hypertension.

Authors:  Pradeep R Rai; Carlyne D Cool; Judy A C King; Troy Stevens; Nana Burns; Robert A Winn; Michael Kasper; Norbert F Voelkel
Journal:  Am J Respir Crit Care Med       Date:  2008-06-12       Impact factor: 21.405

9.  Human herpesvirus-8 infection of primary pulmonary microvascular endothelial cells.

Authors:  Todd M Bull; Christina A Meadows; Christopher D Coldren; Mark Moore; Sylk M Sotto-Santiago; Serge P Nana-Sinkam; Thomas B Campbell; Mark W Geraci
Journal:  Am J Respir Cell Mol Biol       Date:  2008-06-27       Impact factor: 6.914

10.  Safety and tolerability of bosentan in the management of pulmonary arterial hypertension.

Authors:  Kari E Roberts; Ioana R Preston
Journal:  Drug Des Devel Ther       Date:  2009-09-21       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.